JNJJohnson & Johnson

$263.86+40% 1Y

$263.86

$182.8052 weeks$278.28

Is the price fair?

Watch

A demanding price: priced for +11% a year vs +6% a year delivered and at the top of its own P/E range.

2 to watch, 1 without data

What the price assumes~+11% a yearderived · Sep 27, 2026

Priced for ~11% a year FCF growth. The price demands more than its three-year revenue growth of 6% a year, priced for acceleration.

Vs its own P/E rangedearer than 93% of its own historyderived

Expensive vs its own history: P/E 40.0 vs a 20.4 median over 40 quarters (+97% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 81% of the market

FCF yieldbehind 72% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Johnson & Johnson trades at 40.0× earnings against 40.0× for the median Drug Manufacturers - General name, cheaper than its own group.

40.0

Trailing P/E · Drug Manufacturers - General median 40.0 · cheaper than the typical name in its group

Price / sales: 6.39
Price / sales · today's price, trailing year to Sep 27, 2026
Free cash flow yield: 3.2%
Free cash flow yield · Drug Manufacturers - General median 5.5%
Growth the price implies: +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; the business has delivered +9.4% a year over the last three.

Details›

What the market has paid for these earnings: 40 quarters of its own multiple × $6.59 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$113.00
Its own P/E history, median	$134.21
Its own P/E history, upper quartile	$159.20
52-week range	$182.80 – $278.28
Today	$263.86

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.